Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related NVS
Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis
Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients
Valeant: Based On The Novartis Settlement, Phildor Legal Exposure Could Be $860MM (Seeking Alpha)
Related ZIOP
Stocks Hitting 52-Week Highs
Short Selling: Karl Loomes Picks The Six Hottest U.S.-Listed Stocks

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

Oct 2015MainfirstDowngradesUnderperform
Jul 2015Leerink SwannMaintainsOutperform
Jun 2015Bryan GarnierUpgradesNeutralBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (IEX + NVS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters